In the HR+ subgroup, the rate of brain metastasis was significantly higher in HER2 low-expression breast cancers than in HER2-0 breast cancers, and there may be differences in HER2 expression between primary and metastatic foci at different stages of progression. The gene discussed is ERBB2; the disease is breast carcinoma.